Skip to content

A study of determine if genes influence the response to chemotherapy in patients with cancer of the mouth

Understanding the genetic basis of chemotherapy resistance in gingivobuccal squamous cell carcinoma (GSCC)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/09/005002
Enrollment
12
Registered
2014-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patient with Cancer of Gingivobuccal Complex

Interventions

None listed

Sponsors

DBT
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Previously untreated borderline resectable GB SCC i.e T4a lesions 2. Histological proven diagnosis of squamous cell cancer 3. Signed informed consent 4. Adequate organ function • Hematological- Hb > 9 g/dL, ANC >= 1.5 x 109/L, platelets >= 100 x 109/L. • Liver functions- bilirubin=30 g/L. • Renal function- Creatinine 30 mL/min. • Performance score (KPS) > 80 or ECOG

Exclusion criteria

Exclusion criteria: 1. Distant metastasis present 2. Serious co-morbidities such as severe cardiac failure or severe pulmonary compromise or severe and active infections. 3. Patients not suitable for any chemotherapy. 4. Patient is currently enrolled in a clinical trial for another investigational therapy. 5. Pregnancy 6. Patients in whom chemotherapy is advised for a palliative intent will not be considered for the study because chemotherapy will be very varied and may be metronomic in nature which will cause wide differences in the final analysis

Design outcomes

Primary

MeasureTime frame
biomarkers to predict response to chemotherapyTimepoint: 1) Pre treatment: at the time of diagnosis 2) Post treatment: after 2 cycles of chemotherapy. 3) Post surgery: surgery is done in responders after 3 cycles of chemotherapy so, biopsy at surgery will be taken as third time point (post treatment). But in non responders 3rd cycle of chemotherapy is not given if they do not respond to the first two cycles of NACT

Secondary

MeasureTime frame
Identification of novel biomarkerTimepoint: 1) Pre treatment: at the time of diagnosis 2) Post treatment: after 2 cycles of chemotherapy. 3) Post surgery: surgery is done in responders after 3 cycles of chemotherapy so, biopsy at surgery will be taken as third time point (post treatment).

Countries

India

Contacts

Public ContactDr Surajit Dhara

National Institute of Biomedical Genomics (NIBMG)

sd1@nibmg.ac.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026